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Background: The aim of this study was to evaluate the efficacy of a group Cognitive Behavioural Therapy (CBT)
treatment for depression and anxiety in Parkinson’s disease (PD).
Methods: A waitlist-controlled trial design was used. Eighteen adults with PD and a comorbid DSM-IV-TR diagnosis
of depression and/or anxiety were randomised to either Intervention (8-week group CBT treatment) or Waitlist
(8-week clinical monitoring preceding treatment). The Depression, Anxiety, Stress Scale-21 (DASS-21) was the
primary outcome. Assessments were completed at Time 1 (pretreatment), Time 2 (posttreatment/post-waitlist)
and 1-month and 6-month follow-ups.
Results: At Time 2, participants who received CBT reported greater reductions in depression (Mchange = −2.45) than
Waitlist participants (Mchange = .29) and this effect was large, d = 1.12, p = .011. Large secondary effects on anxiety
were also observed for CBT participants, d = .89, p = .025. All treatment gains were maintained and continued to
improve during the follow-up period. At 6-month follow-up, significant and large effects were observed for both
depression (d = 2.07) and anxiety (d = 2.26).
Conclusions: Group CBT appears to be an efficacious treatment approach for depression and anxiety in PD
however further controlled trials with larger numbers of participants are required.
Trial registration: Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12610000455066)
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Randomised controlled trialBackground
Depression and anxiety are the two most clinically signifi-
cant psychiatric syndromes in Parkinson’s disease (PD),
affecting approximately 50% of individuals with PD [1,2],
and negatively affecting functional ability and quality of
life [3]. Pharmacological management currently consti-
tutes the first-line treatment for depression and anxiety in
PD [4] however antidepressant treatments are compli-
cated by concerns regarding polypharmacy and safety, and
the efficacy of such treatments is currently unclear [5]. In
a recent meta-analysis [6], the pooled effect of antidepres-
sants for depression in PD was found to be moderate but
non-significant (d = .71, 95% CI = −1.33 to 3.08).* Correspondence: l.troeung@curtin.edu.au
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reproduction in any medium, provided the orConsequently, there has been an emerging interest in
the utility of alternative treatments for depression and
anxiety in PD in recent years. Several treatments have
been suggested as safer and potentially more effective
alternatives and include dopamine agonists [7], Omega-3
fatty-acid supplementation [8], repetitive transcranial mag-
netic stimulation [9], and cognitive behavioural therapy
(CBT) [10].
CBT has been identified as a particularly viable alterna-
tive to pharmacological regimens [6,11]. A growing body
of preliminary research (i.e., case studies and uncontrolled
trials) currently provides early efficacy support for CBT
for depression and anxiety in PD populations [12-20].
There is particularly strong emerging evidence for the
efficacy of individual CBT interventions in PD. In the first
randomised controlled trial (RCT) of individual CBT forl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[10], statistically significant and large effects on both
depression (d = 1.59) and anxiety (d = .98) were observed
following a 10-week CBT programme and maintained at
one-month follow-up. Group CBT interventions have not
been studied in a controlled trial in PD however, despite
being identified as a highly suitable treatment format for
older adults experiencing psychological difficulties [20].
While there have been a number of recent large group-
based didactic programmes featuring CBT techniques in
PD [21-23], there have only been two studies of group
CBT for clinical depression and/or anxiety in PD; one case
study [17] and one case series [15], for a collective sample
of five participants.
There are several therapeutic advantages associated
with the group treatment modality that may be particu-
larly beneficial for individuals with PD. For example, it is
well documented that older adults and individuals with
chronic illnesses tend to experience increased stigma,
withdrawal, and social isolation due to increased func-
tional impairment [24] and this plays a significant role in
both the development and maintenance of depression
[25]. Group therapy may therefore be particularly
beneficial as it promotes social interaction, mutual
support, and reciprocal validation. Interaction with others
experiencing similar difficulties can also provide an
opportunity to recognise shared experiences and the
universality of concerns [26]. Moreover, group treat-
ment facilitates social and interpersonal learning which
can enhance grasping of cognitive concepts and thereby
enhance the efficacy of treatment [27]. Finally, group
treatment also has practical advantages for healthcare pro-
viders as it is more cost- and time-effective than individual
treatments [28].
The aim of this study was to conduct a randomised
controlled trial of group CBT for depression and anxiety
in PD. We hypothesised that group CBT would result in
greater reductions in depression, anxiety, stress, negative
thoughts, and greater improvements in quality of life than
clinical monitoring.Methods
Ethical approval from the Curtin University Human
Research Ethics Committee was granted for this study.
The study was also registered with the Australian New
Zealand Clinical Trials Registry, and all aspects of the
study conformed to CONSORT requirements [29].Setting
The study took place at Curtin University in Perth,
Western Australia. Two waves of treatment were con-
ducted between July 2010 and October 2011.Research design
Initially, a randomised waitlist-controlled design was used
(see Figure 1). Participants were randomised to either
Intervention (8-week group CBT) or Waitlist conditions
(8-week clinical monitoring preceding treatment). Signi-
ficant recruitment difficulties were experienced during
Wave II of treatment however and all eligible participants
were assigned to the Intervention group. Our study thus
comprises a randomised phase (Wave I) and a non-
randomised phase (Wave II). The final study design was
subsequently a non-randomised waitlist-controlled trial.
Participants and Inclusion/exclusion criteria
Participants were recruited from the Parkinson’s Asso-
ciation of WA, Fremantle Hospital, Michael J Fox
Foundation FoxTrial finder registry and print and online
community newspapers. Inclusion criteria were: minimum
6-month period post-diagnosis of PD, diagnosis of at least
one depressive and/or anxiety disorder according to
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV-TR; [30]) criteria using the Structured Clinical
Interview for DSM (SCID-I/P; [31]), and stabilised use of
medications for three months (antiparkinsonian and anti-
depressants). Exclusion criteria were: mild cognitive im-
pairment or dementia (Telephone Interview for Cognitive
Status-30 score < 18), concurrent psychological treatment,
current psychotic disorder as assessed using the Mini
International Neuropsychiatric Interview 6.0 (MINI) and
high current suicide risk (MINI Suicidality score > 17).
Randomisation
In Wave I, a block randomisation procedure stratified by
timing was used to allocate participants to Intervention
or Waitlist conditions. Randomisation was performed
following recruitment of sufficient participants for an
Intervention and Waitlist group (approximately 10 to 14
participants). Randomisation was completed by an exter-
nal statistician to limit selection bias. A 1:1 ratio was
used. Significant recruitment difficulties were experi-
enced during Wave II and all eligible participants were
assigned to the Intervention group. The final partici-
pant allocation numbers were Intervention (n = 11) and
Waitlist (n = 7).
Sample size calculation
An a priori power analysis determined that a target sam-
ple size of 89 participants was required to sufficiently
power the study at a .80 level (see Additional file 1 for
detailed power calculation).
Procedure
Interested individuals self-referred and were sent an
information pack and consent form. All who provided
written consent were screened by telephone using a semi-
Figure 1 Assessment and measurement data collection points.
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TICS-30 [32], (ii) initial signs of psychopathology using
the MINI-Screen [33], (iii) psychosis, and (iv) serious
suicide risks using the relevant modules of the MINI 6.0
[34]. Suitable individuals were invited to attend an as-
sessment at the Curtin Psychology Clinic. All clinical
assessments were conducted over a two-week period
immediately preceding the first scheduled treatment
session. Assessments involved a structured diagnostic
interview using the SCID-I/P. All individuals meeting
DSM-IV-TR criteria for at least one anxiety or de-
pressive disorder were offered a place in the study
and completed pre-treatment questionnaires as base-
line data. Participants were then randomised to either
Intervention or Waitlist conditions. Those assigned to
the Waitlist condition were advised of an eight-week
period of clinical monitoring preceding treatment, while
those assigned to the Intervention condition commenced
treatment the following week. Post-treatment measures
for the Intervention group were completed immediately
following the end of Session 8 of treatment. Post-waitlist
measures for the Waitlist group were mailed out to
participants following the eight-week period of clinical
monitoring.All assessments were conducted by Curtin University
clinical psychology Masters or Doctoral candidates under
the supervision of the second author (S.E.) who is an
experienced clinical psychologist with numerous years of
clinical practice and research in CBT. A full-day training
session was also provided by the second author for both
telephone and clinical assessments. The authors did not
conduct any of the clinical assessments to limit any poten-
tial selection bias.
Outcome measures
The primary outcomes were depression, anxiety and
stress measured using the Depression, Anxiety and
Stress Scale-21 (DASS; [35]). Secondary outcomes were
quality of life (Parkinson’s Disease Questionnaire-39;
PDQ-39, [36]) and depressive and anxious cognitions
(Cognitions Checklist; CCL, [37]). All scales are valid
and reliable measures and have demonstrated excellent
psychometric properties [35-37].
CBT intervention
The CBT Intervention was an eight-week programme
consisting of eight 2-hour sessions. Each group was
facilitated by two therapists. There were four therapists
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ence and three clinical psychology Masters students. All
therapists received weekly supervision and training with
the second author (S.E) who reviewed session recordings
to ensure treatment adherence and fidelity. The CBT
treatment was an adaptation of a general CBT group
program for anxiety and depression [38]. Main treatment
components were psychoeducation, relaxation training,
cognitive therapy, problem solving, and behavioural acti-
vation. A number of PD-specific adaptations were imple-
mented. Procedural modifications included a significant
reduction of in-session writing, inclusion of regular breaks
throughout each session, and freedom to attend to PD-
related needs at any time. Content modifications were
made to examples in the original protocol to be more age
and disease appropriate. Specific PD sections were also
implemented including; the role of PD, loss and stress in
depression and anxiety, activity scheduling and pacing
around the on-off effect in PD, motor symptoms as trig-
gers for panic and anxiety, the fear of falling, and prepar-
ing for disease progression.
Waitlist condition
It was clearly outlined to all participants that the trial
involved a waitlist-control and informed consent to
participate included agreement to undergo an eight-
week period of clinical monitoring prior to treatment if
assigned to the Waitlist condition. Waitlist participants
were asked to continue with any existing pharmacolo-
gical treatments for depression and/or anxiety (same
medication and dosage) however no new treatments
were to be initiated.
Statistical analyses
Multilevel linear mixed-effects modelling (MLM) was
used to analyse data using the ‘MIXED’ procedure in SPSS
19.0. MLM is a regression based approach which provides
a more powerful means of analysing data collected in
groups when compared with the ANOVA family of
analyses [39]. Statistical analyses were based on the intent-
to-treat sample (n = 18) and tested against an alpha level
of .05 (two-tailed). No adjustments were made for mul-
tiple comparisons.
Acute treatment effects
Six separate analyses were conducted to examine the
trajectory of change in outcomes (DASS-Depression
(DASS-D), DASS-Anxiety (DASS-A), DASS-Stress (DASS-S),
PDQ-39, CCL-Depressive Cognitions (CCL-D), CCL-
Anxious Cognitions (CCL-A)) between Time 1 (pretreat-
ment) and Time 2 (posttreatment/post-waitlist). Each
analysis included four predictors; Time (fixed), Time
(random), Condition (fixed) and the fixed interaction
between Time and Condition (Time × Condition). TheTime × Condition interaction effect was the primary
variable of interest in each analysis. A significant Time ×
Condition interaction effect indicates a differential rate of
change in outcomes between the Intervention and Wait-
list conditions from Time 1 to Time 2. It was predicted
that there would be a significant Time × Condition inter-
action effect for all outcomes, with the Intervention group
experiencing statistically significant improvement between
Time 1 and Time 2 while the Waitlist group did not.
Long-term treatment effects
Another six analyses were conducted to examine the
trajectory of change in outcomes between pretreatment
and six-month follow-up. Due to ethical requirements as
well as the timeframe of the study, the waiting period
for the control participants was limited to only eight
weeks, with Waitlist participants receiving CBT follow-
ing the completion of post-waitlist measures. Follow-up
effects were thus uncontrolled and modelled using data
from Intervention participants only (n = 11). Each ana-
lysis included two predictors; Time (continuous, random)
and Measurement Occasion (categorical, fixed). Of inter-
est in this analysis was the fixed effect of Measurement
Occasion (pretreatment, posttreatment, 1-month follow-
up and 6-month follow-up). A statistically significant slope
at any measurement point for an outcome indicated that
there was a statistically significant rate of change between
pretreatment and the respective time point. It was
predicted that there would be a significant slope at every
time point for every outcome demonstrating sustained
treatment gains for the CBT programme.
Clinically significant change
The clinical significance of any change in DASS-21
scores over the course of treatment was assessed using
the Jacobson and Truax [40] method (see Additional file 2
for a full description of the analyses). Briefly, the Jacobson
and Truax method posits that treatment efficacy can be
indexed by the degree to which individuals return to nor-
mal functioning subsequent to treatment. Four possible
outcomes are proposed; Recovered, Improved, Unchanged
and Deteriorated. Determining which group an individual
belongs depends on; (i) the clinical significance of any
change and, (ii) the reliability of any change as assessed by
the Reliable Change Index (RCI). The midpoint between
the general population mean and clinical population mean
was calculated and used as a cut-off for clinically signi-
ficant change (Method C). The RCI was calculated as per
Jacobson and Truax [33]. A participant was deemed ‘Re-
covered’ if their posttreatment score exceeded the cut-off
and RCI > 1.96. A participant was deemed ‘Improved’
if their posttreatment score exceeded the cut-off but
change to a reliable magnitude was not demonstrated
(RCI < 1.96).
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Given our small sample size, three sensitivity analyses
were conducted to demonstrate that results are robust
to possible confounding and bias. First, we compared
the change in DASS outcomes from Time 1 to Time 2
for Intervention and Waitlist participants from Wave I
only (i.e., the randomised proportion of the trial; n =14).
Second, we examined the change in DASS scores from
Time 1 to Time 2 for individuals with (n = 6) and with-
out (n = 12) a diagnosis of MDD. Finally, we examined
the trajectory of change in DASS scores from pretreat-




Figure 2 outlines the participant flow in the study. A
total of 45 individuals expressed interest in the study.
Sixteen decided not to continue after receiving further
information about the treatment. Reasons for discontinu-
ation included; residence outside of the Perth metropol-
itan area (n = 3), holiday plans coinciding with treatment
dates (n = 2), inability to leave the house due to advanced
disease (n = 1) or no reason given (n = 10). Twenty-nine
participants were screened for eligibility. Eleven parti-
cipants were found to be ineligible due to; cognitive im-
pairment (4 participants; 36%) and no clinically significantFigure 2 Flow diagram of participant recruitment and allocation.(i.e., a DSM-IV-TR diagnosis of) depression and/or anx-
iety (7 participants; 64%). Eighteen adults met eligibility
criteria for the study and comprised the intention-to-treat
(ITT) sample.
Participant characteristics
The ITT sample comprised 12 males (67%) and 6 females
(33%) with a mean age of 66 years. Mean duration of PD
was 5 years (range: 8 months to 20 years). Seventeen
participants had at least one anxiety diagnosis (94%) while
seven participants had at least one depressive diagnosis
(39%). Eighty-nine percent (N = 16) of participants were
currently on antiparkinsonian medications and half were
taking antidepressants. Average pretreatment severity of
depression was Moderate (93rd percentile), anxiety was
Severe (96th percentile), and stress was Moderate (86th
percentile). Table 1 displays demographic and other pre-
treatment clinical data for the sample.
Treatment completion
Sixteen of 18 participants assigned to a treatment condi-
tion completed treatment (attrition rate = 11%). All treat-
ment completers completed the relevant measurements
at posttreatment and follow-ups. For treatment with-
drawers, the Last Observation Carried Forward method
was used as a conservative estimate for posttreatment
and follow-up data.
Table 1 Demographic and baseline clinical data
Total n = 18 Intervention n = 11 Waitlist n = 7 p-value*
Gender, n (%)
Male 12 (67%) 9 (82%) 3 (43%)
Female 6 (33%) 2 (18%) 4 (57%)
Age, M (SD) 66 (8.26) 68 (7.72) 62 (8.34) .17
PD duration (M years, SD) 5.12 (4.61) 5.70 (5.50) 4.29 (3.15) .55
Age of PD onset, M (SD) 61.82 (7.47) 64.10 (7.82) 58.57 (6.00) .13
Mean H&Y stage II II II
Taking antidepressants, n (%) 11 (61%) 6 (55%) 5 (74%)
DSM-IV-TR diagnosis, n (%)
Generalised anxiety 12 (66%) 8 (73%) 4 (57%)
Panic attacks and/or disorder 7 (39%) 4 (35%) 3 (43%)
Major depressive disorder 6 (33%) 2 (18%) 4 (57%)
Dysthymia 6 (33%) 3 (27%) 3 (43%)
Social anxiety 4 (22%) 1 (9%) 3 (43%)
Posttraumatic stress disorder 1 (5%) 0 1 (14%)
Primary outcomes, M (SD)
DASS-D 10.44 (4.23) 10.09 (3.73) 10.71 (5.41) .99
DASS-A 9.06 (3.35) 9.64 (2.01) 8.57 (4.61) .72
DASS-S 9.78 (3.83) 10.64 (3.26) 10.00 (4.28) .56
Secondary outcomes, M (SD)
PDQ-39 34.97 (13.07) 36.03 (12.62) 28.48 (16.15) .27
CCL-D 30.29 (13.30) 31.22 (15.50) 24.49 (14.12) .32
CCL-A 32.41 (12.19) 32.01 (10.51) 29.46 (14.00) .62
DASS-D = DASS-Depression, DASS-A = DASS-Anxiety, DASS-S = DASS-Stress, PDQ-39 = Parkinson’s Disease Questionnaire-39, CCL-D = Cognitions Checklist-Depressive
Cognitions, CCL-A = Cognitions Checklist-Anxious Cognitions.
*p-value for Independent t-test on baseline differences between Intervention and Waitlist groups.
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Primary outcomes
There was a significant differential rate of change in
both depressive and anxiety symptoms between the
Intervention and Waitlist groups from Time and Time 2
(Table 2). Mean reduction in depression for Intervention
participants was 3.91 compared with an increase of .29 for
Waitlist participants, F (1, 16) = 8.31, p = .011, d = 1.12.
Similarly, mean reduction in anxiety for Intervention was
3.64 compared with 0.43 for Waitlist, F (1, 16) = 6.06,
p = .025, d = .89. The Time × Condition effect for
DASS-S scores was non-significant, although there
was a significant main effect for Time, F (1, 31) = 9.04,
p = .005. Thus, both Intervention and Waitlist partici-
pants experienced a reduction in stress over the treatment
period.
Secondary outcomes
For secondary outcomes, there was a significant differ-
ential rate of change in the frequency of depressive and
anxious thoughts between the Intervention and Waitlist
groups from Time 1 to Time 2. Mean reduction in thefrequency of self-reported depressive thoughts was
13.2% for the Intervention group compared with a
4.4% increase in frequency for Waitlist participants,
F (1, 17) = 8.86, p = .009, d = 1.26. Similarly, participants
who received CBT experienced a mean 8.34% reduction in
the frequency of self-reported anxious thoughts while
Waitlist participants experienced a mean increase of
3.58%, F (1, 16) = 8.75, p = .009, d = .92. There were no
significant Time, F (1, 13) = .01, p = .923, or Time ×
Condition effects, F (1, 13) = 3.24, p = .095, for PDQ-39
scores indicating no significant change in quality of life for
both groups between Time 1 and Time 2.Follow-up treatment effects
Longitudinal analyses showed a significant main effect
for all DASS-21 and CCL factors, indicating a statisti-
cally significant rate of change in depression, anxiety,
stress and depressive and anxious thoughts between
pretreatment and six month follow-up. Significant and
large effects were observed for all DASS and CCL factors
at both 1-month and 6-month follow-ups (Table 3).
Table 2 Change in outcomes between time 1 (pretreatment) and time 2 (posttreatment/post-waitlist)
Intervention (n = 11) Waitlist (n = 7)
Outcome Time Mean (SD) Mean (SD) p-value* d**
DASS-D 1 10.09 (3.73) 10.71 (5.41) .011 1.12
2 7.64 (2.77) 11.00 (5.20)
DASS-A 1 9.64 (2.01) 8.57 (4.61) .025 .89
2 6.73 (2.90) 8.14 (4.85)
DASS-S 1 10.64 (3.26) 10.00 (4.28) .828 .08
2 8.82 (1.83) 8.43 (4.50)
PDQ-39 1 36.03 (12.62) 28.48 (16.15) .095 .56
2 32.82 (12.95) 32.88 (14.50)
CCL-D 1 31.22 (15.50) 24.49 (14.12) .009 1.26
2 18.02 (15.94) 28.83 (9.86)
CCL-A 1 32.01 (10.51) 29.46 (14.00) .009 .92
2 23.67 (11.27) 33.04 (15.38)
DASS-D = DASS-Depression, DASS-A = DASS-Anxiety, DASS-S = DASS-Stress, PDQ-39 = Parkinson’s Disease Questionnaire-39, CCL-D = Cognitions Checklist-Depressive
Cognitions, CCL-A = Cognitions Checklist-Anxious Cognitions.
*p-value for Time x Condition interaction effect MTΔ−MCΔSDpooled .
**Cohen’s d as computed by.
Table 3 Change in outcomes for Intervention group
(n = 11) from pretreatment to six-month follow-up
Outcome Time Mean (SD) p-value d**
DASS-D Pretreatment 10.09 (3.73)
Posttreatment 7.64 (2.77) .001 .75
1-month f-up 5.91 (3.27) .000 1.19
6-month f-up 3.82 (2.12) .000 2.07
DASS-A Pretreatment 9.64 (2.01)
Posttreatment 6.73 (2.90) .000 1.17
1-month f-up 5.82 (3.16) .000 1.44
6-month f-up 3.82 (3.03) .000 2.26
DASS-S Pretreatment 10.64 (3.26)
Posttreatment 8.82 (1.83) .031 .69
1-month f-up 6.91 (2.51) .000 1.28
6-month f-up 5.45 (2.98) .001 1.66
PDQ-39 Pretreatment 36.03 (12.62)
Posttreatment 32.82 (12.95) .096 .25
1-month f-up 30.54 (11.99) .024 .45
6-month f-up 32.05 (16.26) .259 .27
CCL-D Pretreatment 31.22 (15.50)
Posttreatment 18.02 (15.94) .016 .84
1-month f-up 16.78 (11.80) .000 1.05
6-month f-up 18.83 (10.45) .002 .94
CCL-A Pretreatment 32.01 (10.51)
Posttreatment 23.67 (11.27) .003 .77
1-month f-up 20.08 (14.68) .000 .94
6-month f-up 16.31 (11.08) .000 1.45
**Cohen’s d as computed by MTime1−MTimeXSDpooled .
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the study period however, F (3, 20) = 2.05, p = .14.Clinically significant change
Table 4 displays the results of the clinically significant
change analyses for each of the DASS factors. There was
a clear trend with higher rates of clinically significant
change (i.e., Improved or Recovered) observed over each
progressive measurement point. At posttreatment, only
11% of participants evidenced clinically significant change
in depression, and 6% for anxiety. However, by 6-month
follow-up, 89% of participants showed clinically significant
improvement in depression, 83% showed clinically sig-
nificant improvement in stress, and 56% showed clinically
significant improvement in anxiety. Thus, CBT appeared
to have a delayed effect with the full benefits of therapy
manifesting in the period following treatment completion.Sensitivity analyses
Sensitivity analysis I
Table 5 displays the results for Sensitivity Analysis I using
data from Wave I participants only (i.e., the randomised
proportion of the trial). Mean change in depression for
participants who received CBT was 4.72 compared to 0.29
for Waitlist, corresponding to a large treatment effect
(d = .94), although this difference was not statistically
significant, F (1, 12) = 3.62, p = .080. There was a significant
difference in change in anxiety scores, however. Mean re-
duction in anxiety for Intervention participants was 3.62
compared with 0.28 for Waitlist, d = .89, F (1, 12) = 9.50,
p = .007.
Table 4 Results of clinically significant and reliable
change analyses (n = 18)
DASS-D DASS-A DASS-S
Post 1 m 6 m Post 1 m 6 m Post 1 m 6 m
Recovered 0 28% 67% 6% 17% 39% 11% 28% 39%
Improved 11% 11% 22% 0 6% 17% 11% 22% 44%
Unchanged 89% 61% 11% 94% 78% 44% 72% 50% 17%
Deteriorated 0 0 0 0 0 0 6% 0 0
Total CSC 11% 39% 89% 6% 23% 56% 22% 50% 83%
DASS-D = DASS-Depression, DASS-A = DASS-Anxiety, DASS-S = DASS-Stress,
Post = posttreatment, 1 m = 1-month follow-up, 6 m = 6-month follow-up,
CSC = clinically significant change (i.e., total percentage of participants who
showed clinically significant positive change).
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Table 6 displays the results for Sensitivity Analysis II
comparing change in DASS outcomes for participants
with and without a diagnosis of MDD. The CBT inter-
vention appeared to have a greater effect on individuals
with MDD. Participants with MDD and who received CBT
demonstrated large reductions in depression (d = 2.09),
anxiety (d = 1.19), and stress (d = 1.10) compared with
Waitlist participants, and all differences were statistically
significant. In contrast, there was a smaller effect on
symptoms for participants without MDD. The effects on
depression and stress were small-to-moderate favouring
CBT, while a large effect on anxiety was observed (d = .84),
however, this effect was not statistically significant.
Sensitivity analysis III
Table 7 displays the results for Sensitivity Analysis III
which examined the trajectory of change from pretreat-
ment to six-month follow-up for Waitlist participants. A
significant main effect was observed for all DASS
factors, indicating a statistically significant rate of change
in symptoms between pretreatment and six month
follow-up. Similar to the results of the follow-up effectsTable 5 Sensitivity analyses I: change in DASS between
Time 1 and Time 2 for wave I participants only
(Randomised proportion of trial; n = 14)
Intervention (n = 7) Waitlist (n = 7)
Outcome Time Mean (SD) Mean (SD) p-value* d**
DASS-D 1 11.00 (3.69) 11.00 (5.17) .030 .94
2 6.28 (2.56) 10.71 (6.13)
DASS-A 1 9.00 (2.31) 8.14 (4.84) .007 .89
2 5.38 (2.56) 7.86 (4.63)
DASS-S 1 10.57 (3.95) 8.71 (2.29) .169 .47
2 8.43 (4.50) 8.14 (4.14)
DASS-D = DASS-Depression, DASS-A = DASS-Anxiety, DASS-S = DASS-Stress,
PDQ-39 = Parkinson’s Disease Questionnaire-39, CCL-D = Cognitions Checklist-
Depressive Cognitions, CCL-A = Cognitions Checklist-Anxious Cognitions.
*p-value for Time x Condition interaction effect.
**Cohen’s d as computed by MTΔ−MCΔSDpooled .for the Intervention group, greater improvement was
observed over each progressive measurement point with
large effects on all DASS scales observed at 6-month
follow-up.
Discussion
Group CBT appeared to be a feasible and efficacious
treatment approach for depression and anxiety in the
sample with an 89% treatment completion rate. At the
end of the eight-week treatment period, participants
who received CBT experienced statistically significant
and large improvements in depression (d = 1.12) and
anxiety (d = .89) relative to waitlist participants. These
results are consistent with posttreatment effect sizes
recently reported by Dobkin and colleagues [10] for
individual CBT for depression in PD (Ham-D, d = 1.57;
BDI, d = 1.1; anxiety; Ham-A, d = .98) and together add
strong support to the growing body of evidence for the
efficacy of CBT for depression and anxiety in PD.
In regards to secondary outcomes, Intervention partici-
pants showed a significant reduction in both self-reported
depressive (d = 1.26) and anxious thoughts (d = .92) rela-
tive to waitlist participants who showed an increase in
negative thinking over the corresponding period. This
finding contributes to a growing number of studies dem-
onstrating simultaneous reductions in depressive and/or
anxiety symptomatology and negative cognitions following
CBT treatment in PD [13,14,19] however further research
is required to establish the mechanisms of change in CBT.
No significant improvement in quality of life was
observed for all participants over the acute treatment
period, which is also consistent with previous CBT in
PD studies also using the PDQ-39 [21-23,41]. This result
may be directly related to the broad nature of the PDQ-
39 which features a large number of questions measur-
ing physical and/or somatic difficulties (e.g., ‘How often
had painful muscle cramps or spasms?’). Reductions in
depression and anxiety are not likely to affect these
physical aspects of life with PD and may explain the lack
of significant change in quality of life ratings in the
present study as well as previous studies.
Long-term treatment effects
This study was also the first to examine the long-term
effects of CBT in PD. To date in the literature, the
maximum length of CBT treatment follow-up has only
been one month [10]. In our study at 6-month follow-up,
significant large effects (ds = .94 to 2.26) were observed
for all outcomes (excluding PDQ-39) and rates of clinic-
ally significant improvement were also strong with 89%
and 56% of participants showing clinically significant
improvement in depression and anxiety, respectively. CBT
appeared to have a delayed effect with the full benefits of
therapy manifesting in the period following treatment
Table 6 Sensitivity analyses II: change in DASS between Time 1 and Time 2 for patients with and without major
depression
With MDD (n = 6) Intervention (n = 4) Waitlist (n = 2)
Outcome Time Mean (SD) Mean (SD) p-value* d**
DASS-D 1 11.00 (4.69) 8.00 (0) .020 2.09
2 5.25 (2.87) 7.5 (0.71)
DASS-A 1 9.75 (2.36) 4.00 (1.41) .050 1.19
2 6.25 (3.3) 4.00 (1.41)
DASS-S 1 11.75 (0.96) 7.50 (3.53) .029 1.10
2 9.75 (0.50) 7.50 (3.53)
Without MDD (n = 12) Intervention (n = 7) Waitlist (n = 5)
Outcome Time Mean (SD) Mean (SD) p-value* d**
DASS-D 1 9.57 (3.36) 12.2 (5.49) .320 .26
2 6.71 (2.29) 10.6 (7.27)
DASS-A 1 9.14 (2.41) 9.80 (4.76) .065 .84
2 5.86 (2.34) 9.40 (4.62)
DASS-S 1 10.00 (4.00) 8.80 (5.17) .365 .38
2 8.29 (2.14) 8.40 (4.72)
DASS-D = DASS-Depression, DASS-A = DASS-Anxiety, DASS-S = DASS-Stress, PDQ-39 = Parkinson’s Disease Questionnaire-39, CCL-D = Cognitions Checklist-Depressive
Cognitions, CCL-A = Cognitions Checklist-Anxious Cognitions.
*p-value for Time x Condition interaction effect.
**Cohen’s d as computed by MTΔ−MCΔSDpooled .
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follow-up in treatment trials. Our sensitivity analysis also
showed that Waitlist participants showed a similar trajec-
tory of change in outcomes for Waitlist participants over
the study period, with significant improvements observed
at every measurement point and the greatest improve-
ment observed at 6-month follow-up (ds = .87 to 2.09).
Delayed treatment effects are common in CBT and psy-
chotherapy in general. Rachman [42] posited that the trueTable 7 Sensitivity analysis III: change in DASS for waitlist
group from pretreatment to six-month follow-up (n = 7)
Outcome Time Mean (SD) p-value d**
DASS-D Pretreatment 11.00 (5.19)
Posttreatment 9.71 (6.13) .012 .23
1-month f-up 5.29 (4.53) .001 1.17
6-month f-up 2.71 (2.14) .004 2.09
DASS-A Pretreatment 8.14 (4.85)
Posttreatment 7.86 (4.63) .014 .06
1-month f-up 6.29 (4.82) .001 .38
6-month f-up 4.29 (3.99) .006 .87
DASS-S Pretreatment 8.42 (4.5)
Posttreatment 8.14 (4.14) .029 .06
1-month f-up 5.43 (4.46) .001 .67
6-month f-up 3.14 (3.02) .004 1.38
**Cohen’s d as computed by MTime1−MTimeXSDpooled .benefits of CBT are commonly not observed until after
the acute treatment period when clients have completed
therapy, acquired the full set of skills necessary to elicit
change, and become more proficient in applying those
skills into their everyday lives.
We acknowledge that our follow-up analyses are based
on uncontrolled data due to the timeframe of the study
and thus should be interpreted with caution. Neverthe-
less, our results provide preliminary support for the
long-term efficacy of CBT in PD which is especially en-
couraging given that one of the most pertinent criticisms
of existing pharmacological regimes for depression and
anxiety relates to questions surrounding the long-term
utility of psychopharmacotherapy and high relapse rates
[43]. The long-term utility of CBT has been attributed to
the focus on self-management and problem solving as
well as the development of skills that enable clients to
address any problems that may arise following cessation
of therapy. Overall, this study supports the assertion
that while there is a broad equivalence in the efficacy
of CBT and pharmacotherapy in the acute phase of
treatment, the long-term utility of CBT may be particu-
larly promising [43].Limitations and direction for future research
While the current sample is the largest for a clinical
group CBT intervention in PD at present, it is acknowl-
edged that the study is underpowered. Although it is
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ted given the sample size, the degree to which these
findings can be generalised beyond the current sample is
restricted. It must be noted that the small sample in the
current study is directly linked with significant and
unexpected recruitment difficulties. Despite widespread
recruitment efforts over a 28-month period, the response
rate for the study was less than 1%. Similar recruitment
difficulties have also been described in previous trials for
depression and/or anxiety in PD [41,44] and may indicate
that there are barriers to seeking psychological treatment
among this population. A recent study [45] of health
service utilisation among a sample of 273 male veterans
with PD showed that only 12.8% of participants were
currently engaged in mental health treatment. The rate of
mental health service utilisation was higher among a
subsample of participants who currently met ICD-9 diag-
nostic criteria for a depressive disorder at 32.3% however
it would still remain that over two-thirds of participants
with a depressive disorder were not currently engaged in
professional treatment. A second recent cross-sectional
survey of 755 people with PD [46] identified several
barriers to mental health service utilisation within this
population including low mental health literacy, accessibil-
ity issues, and PD-specific concerns. Ultimately, effective
treatments are only valuable to the extent that they are
utilised by the targeted population. Continuing research in
this area would be useful for improving the provision of
psychological care to individuals with PD.
Relatedly, as a result of recruitment difficulties, one-
fifth of our study sample was not able to be randomised
to conditions, thus preventing our study from being
classed as a true RCT. Treatment effect sizes presented
may therefore be biased by non-randomisation. How-
ever, our sensitivity analysis using data from only the
randomised phase of our study showed similar results to
the results for the entire sample, with significant and
large effects obtained for both depression (d = .94) and
anxiety (d = .89) relative to Waitlist. This is an encour-
aging finding and suggests that the main treatment effects
we report are robust to any potential confounds due to
non-randomisation.
Other limitations must also be noted. First, participants
with an existing diagnosis of PD were enrolled without
any procedure to assess the validity of symptoms. Second,
the absence of an active control condition inhibits an
examination of the effect of non-specific factors on change
across the study period. While it is encouraging that
reductions in depressive and anxious symptomatology
were associated with comparable reductions in depressive
and anxious thoughts, observed improvements cannot be
solely attributed to CBT. However, it is generally sufficient
to demonstrate efficacy against a non-active control in
pilot studies [47]. Efficacy against active controls (e.g.,alternate psychological intervention, antidepressants) is an
important direction of research for future trials. Second,
due to ethical and time limitations, the control period for
participants in the waitlist condition was only eight weeks.
Thus, follow-up analyses were uncontrolled and may be
overstated. Future trials should implement a longer con-
trol period to provide a more reliable assessment of the
long-term utility of group CBT for depression and anxiety
in PD. Third, the sole use of self-report measures may
present a potential bias. Finally, the sample predominantly
comprised participants in the early stages of PD, with rela-
tively unaffected mobility, no treatment-related dyskinesia,
no cognitive impairment, high quality of life and who were
relatively independent. Thus, the degree to which CBT
may be effective with individuals with PD in the latter
stages of disease and more pronounced motor and cogni-
tive difficulties is not known.
Conclusions
The current interest in CBT treatments within PD stems
from criticisms of existing pharmacological regimes
for depression and anxiety in PD. Overall, this study
provides preliminary support for group CBT as a
treatment approach in PD over both the acute and follow-
up period. Ongoing development and evaluation of
group CBT is needed in light of the limitations of the
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